These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 26237105)
1. Production of Furin-Cleaved Papillomavirus Pseudovirions and Their Use for In Vitro Neutralization Assays of L1- or L2-Specific Antibodies. Wang JW; Matsui K; Pan Y; Kwak K; Peng S; Kemp T; Pinto L; Roden RB Curr Protoc Microbiol; 2015 Aug; 38():14B.5.1-26. PubMed ID: 26237105 [TBL] [Abstract][Full Text] [Related]
2. Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions. Wang JW; Jagu S; Wang C; Kitchener HC; Daayana S; Stern PL; Pang S; Day PM; Huh WK; Roden RB PLoS One; 2014; 9(7):e101576. PubMed ID: 24999962 [TBL] [Abstract][Full Text] [Related]
3. Preparation and properties of a papillomavirus infectious intermediate and its utility for neutralization studies. Wang JW; Jagu S; Kwak K; Wang C; Peng S; Kirnbauer R; Roden RB Virology; 2014 Jan; 449():304-16. PubMed ID: 24418565 [TBL] [Abstract][Full Text] [Related]
4. Roles of Fc Domain and Exudation in L2 Antibody-Mediated Protection against Human Papillomavirus. Wang JW; Wu WH; Huang TC; Wong M; Kwak K; Ozato K; Hung CF; Roden RBS J Virol; 2018 Aug; 92(15):. PubMed ID: 29743371 [TBL] [Abstract][Full Text] [Related]
5. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles. Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749 [TBL] [Abstract][Full Text] [Related]
6. Natural variants in the major neutralizing epitope of human papillomavirus minor capsid protein L2. Seitz H; Schmitt M; Böhmer G; Kopp-Schneider A; Müller M Int J Cancer; 2013 Feb; 132(3):E139-48. PubMed ID: 22961598 [TBL] [Abstract][Full Text] [Related]
7. A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies. Day PM; Pang YY; Kines RC; Thompson CD; Lowy DR; Schiller JT Clin Vaccine Immunol; 2012 Jul; 19(7):1075-82. PubMed ID: 22593236 [TBL] [Abstract][Full Text] [Related]
8. Oral administration of HPV-16 L2 displayed on Lactobacillus casei induces systematic and mucosal cross-neutralizing effects in Balb/c mice. Yoon SW; Lee TY; Kim SJ; Lee IH; Sung MH; Park JS; Poo H Vaccine; 2012 May; 30(22):3286-94. PubMed ID: 22426329 [TBL] [Abstract][Full Text] [Related]
10. A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2. Tumban E; Peabody J; Peabody DS; Chackerian B PLoS One; 2011; 6(8):e23310. PubMed ID: 21858066 [TBL] [Abstract][Full Text] [Related]
11. Nasal immunization of mice with peptide having a cross-neutralization epitope on minor capsid protein L2 of human papillomavirus type 16 elicit systemic and mucosal antibodies. Kawana K; Kawana Y; Yoshikawa H; Taketani Y; Yoshiike K; Kanda T Vaccine; 2001 Jan; 19(11-12):1496-502. PubMed ID: 11163673 [TBL] [Abstract][Full Text] [Related]
12. Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16. Varsani A; Williamson AL; de Villiers D; Becker I; Christensen ND; Rybicki EP J Virol; 2003 Aug; 77(15):8386-93. PubMed ID: 12857908 [TBL] [Abstract][Full Text] [Related]
13. Impact of inhibitors and L2 antibodies upon the infectivity of diverse alpha and beta human papillomavirus types. Kwak K; Jiang R; Wang JW; Jagu S; Kirnbauer R; Roden RB PLoS One; 2014; 9(5):e97232. PubMed ID: 24816794 [TBL] [Abstract][Full Text] [Related]
15. Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions. Smith JF; Brownlow M; Brown M; Kowalski R; Esser MT; Ruiz W; Barr E; Brown DR; Bryan JT Hum Vaccin; 2007; 3(4):109-15. PubMed ID: 17611417 [TBL] [Abstract][Full Text] [Related]
16. Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes. Godi A; Boampong D; Elegunde B; Panwar K; Fleury M; Li S; Zhao Q; Xia N; Christensen ND; Beddows S J Virol; 2020 Nov; 94(24):. PubMed ID: 32967963 [TBL] [Abstract][Full Text] [Related]
17. Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies. Day PM; Gambhira R; Roden RB; Lowy DR; Schiller JT J Virol; 2008 May; 82(9):4638-46. PubMed ID: 18305047 [TBL] [Abstract][Full Text] [Related]
18. Production of Human papillomavirus pseudovirions in plants and their use in pseudovirion-based neutralisation assays in mammalian cells. Lamprecht RL; Kennedy P; Huddy SM; Bethke S; Hendrikse M; Hitzeroth II; Rybicki EP Sci Rep; 2016 Feb; 6():20431. PubMed ID: 26853456 [TBL] [Abstract][Full Text] [Related]
20. Type-specific and cross-reactive antibodies induced by human papillomavirus 31 L1/L2 virus-like particles. Xu Y; Wang Q; Han Y; Song G; Xu X J Med Microbiol; 2007 Jul; 56(Pt 7):907-913. PubMed ID: 17577054 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]